Recursion Pharmaceuticals (RXRX) Cash from Investing Activities (2020 - 2026)

Recursion Pharmaceuticals has reported Cash from Investing Activities for 7 years, with the latest figure at -$338000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 95.35% year-over-year to -$338000.0; the trailing twelve-month figure through Mar 2026 stood at -$9.9 million (down 103.83% YoY), and the FY2025 full-year result was -$16.9 million, down 106.49% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$338000.0, up from -$1.2 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $275.5 million in Q4 2024, with the low at -$8.0 million in Q4 2022.
• Historically, Cash from Investing Activities has averaged $25.1 million across 5 years, with a median of -$2.5 million in 2023.
• The largest YoY upside for Cash from Investing Activities was 11171.38% in 2024 against a maximum downside of 1214.7% in 2024.
• Recursion Pharmaceuticals' Cash from Investing Activities stood at -$8.0 million in 2022, then surged by 68.82% to -$2.5 million in 2023, then soared by 11171.38% to $275.5 million in 2024, then sank by 100.45% to -$1.2 million in 2025, then soared by 72.83% to -$338000.0 in 2026.
• The last three Cash from Investing Activities figures came in at -$338000.0 (Q1 2026), -$1.2 million (Q4 2025), and -$2.5 million (Q3 2025), per Business Quant data.